Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that it has appointed Erik Björk as Chief Financial Officer effective January 3, 2018.
Erik Björk will join Medivir from AstraZeneca where he has been the CFO for Sweden Operations. He has extensive experience as a global financial leader having previously held various financial roles including division CFO, financial planning and controller positions, at Proctor & Gamble in Switzerland, the UK and Sweden. Erik has a MSc in Business and Economics and a Master of Laws both from Lund University.
“I am delighted to welcome Erik to Medivir. He brings a combination of industry experience in strong operating companies and specialized investment and financial reporting skills and we look forward to his contributions in supporting Medivir’s growth.” says Christine Lind, CEO at Medivir.
Erik will be a member of the Medivir Executive Team and report to Christine Lind, CEO. His responsibilities will include leading the operational activities of the Finance & Administration function and Investor Relations.
“Medivir’s mission to bring transformative drugs to patients gives it a clear purpose, strong values and a positive culture. I am excited to become part of a company that has already achieved so much, that has a strong development pipeline, and to assist in realizing the company’s potential” says Erik Björk.
For further information, please contact:
Christine Lind, CEO Medivir AB, phone: +46 (0)8-407 46 41
Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on 3 November 2017.
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.